CompletedNot Applicable

Alpha-lipoic Acid in Diabetic Patients With Ischemic Cardiomyopathy

Egypt60 participantsStarted 2023-03-01

Plain-language summary

The aim of this study is to investigate the effect of alpha-lipoic acid on inflammatory markers and cardiac fibrosis markers in diabetic patients with Ischemic Cardiomyopathy.

Who can participate

Age range20 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria: * Type 2 diabetes with a history of CAD. * LV ejection fraction (LVEF) ≤40%. * Ischemic heart failure patients with NYHA grade II-IV. Exclusion criteria: * Type 1 diabetes. * Severe CKD with GFR ≤ 15 ml/min/1.73m\^2. * Severe liver disease. * Thyroid disorders. * Acute febrile illness. * Autoimmune disorders or connective tissue disorders.

What they're measuring

C-reactive protein (CRP)

Timeframe: 3 month

Tumor necrosis factor alpha (TNFα)]

Timeframe: 3 Months

Transforming growth factor beta (TGFβ)

Timeframe: 3 Months

Matrix metalloproteinase 2 (MMP-2)

Timeframe: 3 Months

Trial details

NCT IDNCT06056687

SponsorDamanhour University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-31

View on ClinicalTrials.gov More Ischemic Cardiomyopathy trials